Press Release: Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference

Geneva, Switzerland, August 31, 2020 - Addex Therapeutics Ltd (SIX and

Nasdaq: ADXN), a leading company pioneering allosteric modulation-based

drug discovery and development today announced that that Tim Dyer, Chief

Executive Officer, is scheduled to participate at the Biotechgate

Digital Partnering Conference taking place on August 31 -- September 3,

2020.

Mr. Dyer and Dr. Lütjens will be available for one-on-one meetings

during the conference. Meetings can be requested via the

https://www.globenewswire.com/Tracker?data=MRfSUsr8eIN8TBT1cf7TI9D9k156tE8PfWsZn_IlHlrvQCStzZ8DKYLpK1x8Hl_b6vLpA3kn-lxeiwaEyR-5kknXEUtB9oUt3LCzI_AXacFqtJBnpzq2E1YasF4UhZYf

Partnering Biotech Webpage for those who registered to participate.

About Addex Therapeutics

https://www.globenewswire.com/Tracker?data=Q2fo9M7FV6Nwg9-tPUD-lX0Pu-K1y6t7_HZHO2IUlnGdaLS4LixUYbk9A8kx_wJEyiJ2__Dujl5co4D9DVv9Xz03h_GtVanGuOo6QOvFnb4=

Addex Therapeutics is a clinical-stage pharmaceutical company focused on

the development and commercialization of an emerging class of novel

orally available small molecule drugs known as allosteric modulators for

neurological disorders. Allosteric modulators offer several potential

advantages over conventional non-allosteric molecules and may offer an

improved therapeutic approach to conventional "orthosteric" small

molecule or biological drugs. Addex's allosteric modulator drug

discovery platform targets receptors and other proteins that are

recognized as essential for therapeutic intervention. Addex's lead drug

candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is

scheduled to enter a pivotal registration clinical trial for Parkinson's

disease levodopa induced dyskinesia (PD-LID). In parallel,

dipraglurant's therapeutic use in dystonia is being investigated in

preclinical models. Addex's second clinical program, ADX71149 (mGlu2

positive allosteric modulator or PAM) is being developed in

collaboration with Janssen Pharmaceuticals, Inc for the treatment of

epilepsy. In addition, Addex's GABA(B) PAM program has been licensed to

Indivior PLC for the treatment of addiction. Preclinical programs

include GABA(B) PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild

neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3

PAM for neurodegenerative disorders.

Press Contacts:

Tim Dyer Mike Sinclair

Chief Executive Officer Partner, Halsin Partners

Telephone: +41 22 884 15 55 +44 (0)20 7318 2955

Email: mailto:PR@addextherapeutics.com mailto:msinclair@halsin.com msinclair@halsin.com

PR@addextherapeutics.com

--------------------------------------- -------------------------------------------------

Disclaimer / Forward-looking statements: This communication does not

constitute an offer or invitation to subscribe for or purchase any

securities of Addex Therapeutics Ltd. This publication may contain

certain forward-looking statements concerning the Company and its

business. Such statements involve certain risks, uncertainties and other

factors which could cause the actual results, financial condition,

performance or achievements of the Company to be materially different

from those expressed or implied by such statements. Readers should

therefore not place undue reliance on these statements, particularly not

in connection with any contract or investment decision. The Company

disclaims any obligation to update these forward-looking statements.

(END) Dow Jones Newswires

August 31, 2020 01:00 ET (05:00 GMT)